Circulating microRNAs from the Molecular Mechanisms to Clinical Biomarkers: A Focus on the Clear Cell Renal Cell Carcinoma

Tito, Claudia; Falco, Elena De; Rosa, Paolo; Iaiza, Alessia; Fazi, Francesco; Petrozza, Vincenzo; Calogero, Antonella

doi:10.3390/genes12081154

Cited by 16 publications

(18 citation statements)

References 157 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, miRNAs can distinguish between benign and malignant renal tumors, as well as distant metastases and non-metastatic tumors. 104 However, there are still some problems to be solved in the research field of miRNA, such as why do mutation occur in the VHL gene, whether there is uniformity of miRNA expression in patients of different regions. Poor tissue-specific targeting, off-target effects and the low safety also need to overcome if developing miRNA therapy.…”

Section: Discussionmentioning

confidence: 99%

MicroRNAs in Body Fluids: A More Promising Biomarker for Clear Cell Renal Cell Carcinoma

Shi¹,

Wang²,

Li³

et al. 2021

CMAR

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is the second most common cancer of the urinary system, accounting for approximately 10-15% of kidney cancers in the world. Clear cell renal cell carcinoma (ccRCC) is the most common RCC subtype with the highest mortality. Surgical resection or puncture of tumor tissue is still an important clinical treatment and diagnosis of ccRCC, but its high recurrence rate and poor prognosis often lead to the short survival period of patients. Hence, the development of novel molecular biomarkers is of great clinical importance. miRNAs are endogenous non-coding small RNAs with a length of 19-24 nt. A growing number of studies have reported that miRNAs, as proto-oncogenes or tumor suppressor genes, play a key role in the development of ccRCC and might be effective diagnostic and prognostic biomarkers. In addition, miRNAs can also predict the efficacy of treatment drug, thus improving the accuracy of clinical medication. Furthermore, noninvasive detection of miRNAs or extracellular vesicles (EV) in body fluids has better convenience and repeatability, which shows remarkable advantages compared with tissue detection. In this review, we summarized the typical miRNAs reported in recent years and place emphasis on evaluating miRNAs in different body fluids to provide reference for the clinical diagnosis and prognosis of ccRCC in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNAs in Body Fluids: A More Promising Biomarker for Clear Cell Renal Cell Carcinoma

Shi¹,

Wang²,

Li³

et al. 2021

CMAR

View full text Add to dashboard Cite

show abstract

“…Consequently, miR-223 plays a significant role in cancers, such as gastric, hepatocellular, ovarian, lung, and esophageal cancers [ 25 , 26 ]. miR-223 downregulation is correlated with the development of chronic lymphocytic leukemia and primary small cell lung cancer (SCLC) [ 26 , 27 ] while its upregulation is associated with ovarian and colorectal cancers. In particular, miR-223 is regarded as a possible biomarker in recurrent ovarian cancer.…”

Section: Mir-223 and Cancermentioning

confidence: 99%

“…For future diagnostic strategies, miR-223 expression can be used to distinguish carcinomas from noncancerous lesions. microRNA-223 can also be considered a therapeutic target for cancer treatment [ 27 ] ( Figure 1 ).…”

Section: Mir-223 and Cancermentioning

confidence: 99%

See 1 more Smart Citation

Relevance of miR-223 as Potential Diagnostic and Prognostic Markers in Cancer

Aziz

Chakraborty

Khan

et al. 2022

Biology

View full text Add to dashboard Cite

In 1993, the discovery of microRNAs in Caenorhabditis elegans (C. elegans) altered the paradigmatic view of RNA biology and post-transcriptional gene regulation. Further study revealed the role of microRNAs in disease development and progression. In particular, this review highlights microRNA-223 (miR-223 or miRNA-223) expression in malignant neoplastic disorders. miR-223 expression controls aspects of hematopoiesis and apoptosis, and cell proliferation, migration, and invasion. miR-223 regulates a number of gene targets, including cytoplasmic activation/proliferation-associated protein-1 (Caprin-1), insulin-like growth factor-1 receptor (IGF-1R), and other cell proliferation- and cell cycle-associated genes. Several studies have proposed miR-223 as a novel biomarker for early cancer diagnosis. Here, we emphasize miR-223′s role in the development and progression of cancer.

show abstract

“…Among them, kidney renal clear cell carcinoma (KIRC) is the most common subtype (accounting for 70–80% of all RCC cases), and it is also one of the most aggressive subtypes with the worst prognosis ( Linehan, 2012 ; Vuong et al, 2019 ). These tumors are asymptomatic in the early stages of the disease and are usually diagnosed by complications of distant metastasis in the later stages ( Hsieh et al, 2017 ; Tito et al, 2021 ), 60% of patients with renal clear cell carcinoma die within 1–2 years after diagnosis, and 30% of patients have distant metastases at the time of diagnosis ( Casuscelli et al, 2019 ). Treatment of KIRC can be partial or radical nephrectomy, ablation therapy, and active monitoring of KIRC, while metastatic tumors are treated with therapeutic action, but the overall prognosis is still limited, and immune-related adverse events still need to be improved ( Choueiri and Motzer, 2017 ; Loo et al, 2019 ; Hofmann et al, 2020 ; Rizzo et al, 2021 ).…”

Section: Instructionmentioning

confidence: 99%

Identification of a Novel Defined Immune-Autophagy-Related Gene Signature Associated With Clinical and Prognostic Features of Kidney Renal Clear Cell Carcinoma

Zhang¹,

Zhang²,

Sun³

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Background: As a common cancer of the urinary system in adults, renal clear cell carcinoma is metastatic in 30% of patients, and 1–2 years after diagnosis, 60% of patients die. At present, the rapid development of tumor immunology and autophagy had brought new directions to the treatment of renal cancer. Therefore, it was extremely urgent to find potential targets and prognostic biomarkers for immunotherapy combined with autophagy.Methods: Through GSE168845, immune-related genes, autophagy-related genes, and immune-autophagy-related differentially expressed genes (IAR-DEGs) were identified. Independent prognostic value of IAR-DEGs was determined by differential expression analysis, prognostic analysis, and univariate and multivariate Cox regression analyses. Then, the lasso Cox regression model was established to evaluate the correlation of IAR-DEGs with the immune score, immune checkpoint, iron death, methylation, and one-class logistic regression (OCLR) score.Results: In this study, it was found that CANX, BID, NAMPT, and BIRC5 were immune-autophagy-related genes with independent prognostic value, and the risk prognostic model based on them was well constructed. Further analysis showed that CANX, BID, NAMPT, and BIRC5 were significantly correlated with the immune score, immune checkpoint, iron death, methylation, and OCLR score. Further experimental results were consistent with the bioinformatics analysis.Conclusion: CANX, BID, NAMPT, and BIRC5 were potential targets and effective prognostic biomarkers for immunotherapy combined with autophagy in kidney renal clear cell carcinoma.

show abstract

Circulating microRNAs from the Molecular Mechanisms to Clinical Biomarkers: A Focus on the Clear Cell Renal Cell Carcinoma

Cited by 16 publications

References 157 publications

MicroRNAs in Body Fluids: A More Promising Biomarker for Clear Cell Renal Cell Carcinoma

MicroRNAs in Body Fluids: A More Promising Biomarker for Clear Cell Renal Cell Carcinoma

Relevance of miR-223 as Potential Diagnostic and Prognostic Markers in Cancer

Identification of a Novel Defined Immune-Autophagy-Related Gene Signature Associated With Clinical and Prognostic Features of Kidney Renal Clear Cell Carcinoma

Contact Info

Product

Resources

About